Faced with a pushback from European regulators, Ultragenyx today says that it is jerking its application for a conditional approval of its drug for GNE Myopathy.
Ultragenyx had hoped to score an early OK on Phase II data for Aceneuramic Acid Prolonged Release (Ace-ER). But regulators shook their heads on that idea. Now the Novato, CA-based rare disease specialist says it plans to regroup and go at this again with late-stage data in H2 2017.
Shares of Ultragenyx slid 5% in pre-market trading.
According to the biotech:
During the Committee for Medicinal Products for Human Use (CHMP) meeting, the CHMP indicated that the Phase 2 study was encouraging but did not provide a sufficient amount of evidence to support an approval at this time. Ultragenyx intends to obtain additional efficacy data from its fully-enrolled global phase 3 study to confirm the effects of Ace-ER, and plans to submit an MAA for full approval after data from this study are available in the second half of 2017.
“Our Phase 3 study is on track and is designed to confirm the encouraging results seen in the Phase 2 study through a larger trial with a primary endpoint and a placebo period that lasts for the full 48-week duration of the study,” said Ultragenyx CEO Emil D. Kakkis.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,000+ biopharma pros who read Endpoints News by email every day.Free Subscription